home / stock / ptct / ptct quote
Last: | $29.09 |
---|---|
Change Percent: | -0.14% |
Open: | $29.48 |
Close: | $29.09 |
High: | $29.83 |
Low: | $29 |
Volume: | 807,280 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$29.09 | $29.48 | $29.09 | $29.83 | $29 | 807,280 | 03-28-2024 |
$29.44 | $28.18 | $29.44 | $29.85 | $27.91 | 436,870 | 03-27-2024 |
$27.96 | $29.38 | $27.96 | $29.47 | $27.92 | 631,358 | 03-26-2024 |
$28.86 | $29 | $28.86 | $29.76 | $28.29 | 363,822 | 03-25-2024 |
$29.09 | $30.2 | $29.09 | $30.46 | $29.05 | 462,811 | 03-22-2024 |
$30.17 | $29.97 | $30.17 | $30.945 | $29.42 | 697,551 | 03-21-2024 |
$29.51 | $30.66 | $29.51 | $30.67 | $29 | 782,919 | 03-20-2024 |
$30.43 | $28.93 | $30.43 | $30.81 | $28.505 | 725,408 | 03-19-2024 |
$29.01 | $29.43 | $29.01 | $29.84 | $28.57 | 690,650 | 03-18-2024 |
$29.55 | $28.79 | $29.55 | $29.915 | $28.71 | 2,231,588 | 03-15-2024 |
$28.89 | $30.36 | $28.89 | $30.36 | $28.25 | 881,839 | 03-14-2024 |
$30.79 | $31.72 | $30.79 | $32.23 | $30.58 | 819,995 | 03-13-2024 |
$31.69 | $30.63 | $31.69 | $31.74 | $30.11 | 760,855 | 03-12-2024 |
$30.7 | $31.19 | $30.7 | $31.66 | $30.57 | 906,560 | 03-11-2024 |
$31.16 | $31.34 | $31.16 | $31.65 | $30.545 | 616,171 | 03-08-2024 |
$30.76 | $31.17 | $30.76 | $31.285 | $30.6 | 654,022 | 03-07-2024 |
$30.88 | $31.87 | $30.88 | $31.9 | $30.175 | 740,932 | 03-06-2024 |
$31.3 | $30.71 | $31.3 | $31.58 | $30.25 | 779,615 | 03-05-2024 |
$30.98 | $32.71 | $30.98 | $32.77 | $30.08 | 1,151,608 | 03-04-2024 |
$31.95 | $26.5 | $31.95 | $32.905 | $25.4 | 2,092,151 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA PR Newswire - First marketing authorization submission for sepiapterin with additional global submissions to follow in 2024 - SOUTH PLAINFIELD, N.J. , March 28, 2024 /PRNewswire/ --...
PTC Therapeutics Provides Key Regulatory Updates PR Newswire - BLA submitted to FDA for Upstaza™ for the treatment of AADC deficiency - - NDA to be submitted mid-year for Translarna™ based on FDA feedback - SOUTH PLAINFIELD, N.J...
2024-03-04 12:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...